



COPY OF PAPERS
ORIGINALLY FILED

Attorney's Docket No.: 13425-053001 / 00395-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lars Abrahmsén et al.

Art Unit : 1645

Serial No. : 10/081,408

Examiner : Unknown

Filed : February 21, 2002

Title : METHODS FOR PROTEIN PURIFICATION

Commissioner for Patents
Washington, D.C. 20231


TRANSMITTAL OF CERTIFIED PRIORITY DOCUMENT UNDER 35 USC §119

In accordance with the provisions of 35 U.S.C. §119, applicants hereby claim priority of Swedish Patent application No. 0100625-3, filed February 23, 2001. A certified copy of the application is submitted herewith. As the priority application is in the English language, all of the requirements of §119 have been met.

Please apply any charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 13425-053001.

Respectfully submitted,

Date: May 6, 2002



Jack Brennan
Reg. No. 47,443

Fish & Richardson P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

20431101.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit

Signature

May 6, 2002

Darlene J. Morin

Darlene J. Morin
Typed or Printed Name of Person Signing Certificate

PRV

PATENT- OCH REGISTRERINGSVERKET
Patentavdelningen



~~NEP~~
~~NEP~~

Intyg Certificate

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

(71) *Sökande* **Biovitrum AB, Stockholm SE**
Applicant (s)

(21) *Patentansökningsnummer* **0100625-3**
Patent application number

(86) *Ingivningsdatum* **2001-02-23**
Date of filing

Stockholm, 2002-04-15

För Patent- och registreringsverket
For the Patent- and Registration Office

Hjördis Segerlund
Hjördis Segerlund

Avgift
Fee **170:-**

METHODS FOR PROTEIN PURIFICATION

TECHNICAL FIELD

5 The present invention relates to a recombinant construct comprising a nucleotide sequence encoding a fusion protein comprising a soluble form of human SSAO (Semicarbazide-Sensitive Amine Oxidase), a secretable fusion partner, a signal peptide; and a protease cleavage site. The invention also relates to methods for purification of a soluble form of human SSAO, said methods utilizing the recombinant construct.

10

BACKGROUND ART

Semicarbazide-Sensitive Amine Oxidases (SSAOs) belong to the copper-containing 15 amine oxidase family of enzymes (CuAO; EC.1.4.3.6) and are widely distributed among both eukaryotic and prokaryotic organisms (Buffoni, 1993). The physiological role of this abundant enzyme is essentially unknown and endogeneous substrates with high affinity have so far not been identified, although benzylamine is an artificial high-affinity substrate (Buffoni, 1993; Callingham et al., 1995; Lyles, 1996, Hartmann and 20 McIntire, 1997; Holt et al., 1998). In humans high SSAO activity is found in vascular smooth muscle cells (Lewinsohn 1984; Nakos and Gossrau, 1994; Yu et al., 1994; Lyles and Pino, 1998; Jaakkola et al., 1999). SSAO activity has also been detected in smooth muscle cells of non-vascular type and in endothelial cells (Lewinsohn, 1984; Castillo et al., 1998; Jaakkola et al., 1999). Small amounts of SSAO protein is also found in blood 25 showing similar properties compared to the tissue-bound form (Yu and Zuo, 1993; Yu et al., 1994; Kurkijärvi et al., 1998).

Many studies have demonstrated that SSAO activity in blood plasma is elevated in 30 several human conditions such as heart failure, atherosclerosis and diabetes (Lewinsohn, 1984; Boomsma et al., 1997; Ekblom, 1998; Boomsma et al., 1999; Meszaros et al., 1999). The mechanism(s) underlying these alterations of enzyme activity are currently uncharacterized. It has been suggested that reactive aldehydes and hydrogen peroxide produced by endogenous amine oxidases could be causative or

contribute to the progression of cardiovascular diseases, and that inhibition of SSAO activity in diabetics might decrease vascular complications (Ekblom, 1998).

Recently it was found that the cDNA sequence of human SSAO (Zhang and McIntire, 1996) is identical to the vascular adhesion protein 1 (VAP-1), which participates in lymphocyte recirculation by mediating the binding of lymphocytes to peripheral lymph node vascular endothelial cells (Smith et al., 1998; see also WO 98/53049). The cDNA sequence of SSAO / VAP-1 is deposited under GenBank Accession Nos. U39447 and NM_003734 (SEQ ID NO: 1). VAP-1 has also been found to be up-regulated on the endothelial cell surface under inflammatory conditions (Smith et al., 1998). However, the adhesive properties of SSAO have only been found in endothelial cells. In smooth muscle cells, SSAO does not support binding of lymphocytes (Jaakola et al., 1999). DNA-sequence analysis, structural modeling and experimental data suggest that human SSAO is a homodimeric glycoprotein consisting of two 90-100 kDa subunits anchored to the plasma membrane by a single N-terminal membrane spanning domain (Morris et al., 1997; Smith et al., 1998; Salminen et al., 1998).

No reports have so far been published regarding the purification of a recombinant mammalian SSAO or purification to near homogeneity of larger amounts of a human SSAO from a natural source. One report has described the use of a FLAG peptide fused to the N-terminal end of full-length human SSAO for detection purposes, but no results were presented regarding its use for purification of the human SSAO protein (Smith et al., 1998). Monoclonal antibodies have been used to immunoaffinity purify small amounts of human SSAO from serum and tissue homogenates for immunoblotting (Smith et al., 1998; Kurkijärvi et al., 1998). Consequently, there is a need for alternative methods for the purification of human SSAO in significant amounts.

Glutathione S-transferase (GST) from *Schistosoma japonicum* is a homodimeric cytoplasmic enzyme that can be purified by affinity chromatography using immobilized cofactor glutathione, followed by competitive elution using reduced glutathione (GSH). Taking advantage of this specific interaction, a gene fusion system for *E. coli* intracellular expression was developed by Smith and co-workers (Smith & Johnson, 1988; see also WO 88/09372) to facilitate detection and purification of recombinant

proteins fused to GST. A potential drawback with using GST as fusion partner is the possibility that the free cysteines on its surface can crosslink with free cysteines on e.g. the fused target protein when exposed to an oxidizing environment. To minimize this risk and to allow for secretion of GST-fusion proteins a mutant form of GST was 5 recently developed, which retain both its ability to form homo-dimers and its enzyme activity (Tudyka and Skerra, 1997). The homo-dimerization propensity of GST can be used to provoke dimerization of the fused target protein e.g. for the purpose of increased avidity effects (Tudyka and Skerra, 1997).

10 Alternative homodimeric fusion partners described in the literature are e.g. the Fc region of immunoglobulins (Hollenbaugh et al., 1992; Sakurai et al., 1998; Lo et al., 1998; Dwyer et al., 1999) and leucine zippers such as GCN4 (Rieker and Hu, 2000; Müller et al., 2000). Several different proteins have been fused to these homodimeric protein domains for different purposes e.g. to increase avidity (Dwyer et al., 1999; 15 Müller et al., 2000) and to restore high-affinity DNA binding of truncated DNA-binding proteins (Rieker and Hu, 2000). Fc-fusion protein can be purified by protein A-affinity chromatography involving elution with low pH buffers (Sakurai et al., 1998; Lo et al., 1998), which may decrease activity of the fused target protein (Gräslund et al., 1997). Another problem associated with using Fc as fusion partner is the use of serum for cell 20 growth, which complicate detection and purification of secreted Fc-fusions since serum contains large amounts of immunoglobulins (Sakurai et al., 1998). The leucine zipper GCN4 has mostly been used as fusion partner for proteins expressed in *E. coli* (Müller et al., 2000) and an affinity-tag might has to be fused to facilitate purification.

25

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1

Schematic illustration of the GST-SSAO DNA construct. The three cysteine to serine 30 mutations (residues 85, 138, and 178 according to the sequence having GenBank Accession No. M14654) in the GST fusion partner are shown with boldface letters. Boxed sequence represents the recognition sequence for the 3C-protease.

Fig. 2

Overview of the SSAO purification process. The determined specific activities for each purification step are indicated.

5

Fig. 3

Schematic illustration of the GST-SSAO expression vector designated pMB887.

10 DISCLOSURE OF THE INVENTION

According to the present invention, it has unexpectedly been found that soluble human SSAO can be produced in milligram quantities in a purification system utilizing a fusion partner capable of enabling dimerization of soluble SSAO. Consequently, in a first 15 aspect this invention provides a recombinant construct comprising a nucleotide sequence encoding a fusion protein comprising (i) a soluble form of human SSAO; (ii) a secretable fusion partner enabling dimerization of SSAO; (iii) a signal peptide allowing for secretion of a polypeptide from a host cell into the 20 culture medium; and (iv) a protease cleavage site located between the human SSAO variant and the fusion partner.

As will be understood by the skilled person, the recombinant construct can optionally 25 comprise one or more nucleotide sequences coding for spacer amino acid sequences of various lengths. Such spacer sequences could be used in order to increase the flexibility within the fusion protein, or to increase the space between protein domains so that folding can take place independently of adjacent domains. Further, spacers could be useful for increasing the accessibility for a protease to cleave at an introduced cleavage 30 recognition sequence.

The said soluble form of human SSAO is preferably lacking the membrane spanning portion of wild-type human SSAO. The membrane spanning portion of the SSAO

polypeptide is known in the art (Morris et al., 1997; Holt et al., 1998; Smith et al., 1998) and is essentially set forth as amino acids 5 to 27, in particular amino acids 6 to 26, of SEQ ID NO: 2.

- 5 The amino acid sequence for human SSAO, excluding the membrane spanning portion, preferably comprises, or essentially consists of, positions 29 to 763 in SEQ ID NO: 2. However, the skilled person will understand that a part of the membrane-spanning portion could be included in the SSAO polypeptide while the polypeptide would still retain its essentially soluble properties. Consequently, the amino acid sequence for
- 10 human SSAO could comprise e.g. positions 27 to 763, or 28 to 763, of SEQ ID NO: 2, including fragments thereof having substantially the biological activities of human SSAO. Further, the term "human SSAO polypeptide" is intended to encompass mutants and naturally occurring variants of human SSAO, either having retained enzymatic activity or protein interaction (e.g. adhesion function), or designed to facilitate structural
- 15 studies (e.g. improved properties for crystallization), or mutated to facilitate studies of structure/function relationships (which also includes inactive mutants).

The fusion partner can be fused to the C-terminal or N-terminal portion of the human SSAO polypeptide. It is envisaged that the fusion protein could comprise more than one fusion partner, for instance one fused to the N-terminal and one fused to the C-terminal part of SSAO. An additional fusion partner could be an additional affinity tag, or a reporter protein such as Enhanced Green Fluorescent Protein (EGFP).

A large number of different gene fusion systems and fusion partners have been described. In such systems, different types of interactions, such as enzyme–substrate, bacterial receptor–serum protein, polyhistidines–metal ion, and antibody–antigen, have been utilized (Uhlén et al., 1992). Various gene fusion systems for affinity purification are also known in the art. Examples of fusion partners used in such systems (for reviews, see e.g. Nilsson et al., 1997; or Sheibani, 1999) comprise staphylococcal Protein A and its derivative Z; the albumin-binding protein from streptococcal Protein G; glutathione S-transferase (GST); polyhistidine tags; biotinylated affinity tags (e.g Biotin AviTag); *E. coli* maltose-binding protein; cellulose binding domains; the FLAG peptide; and *Strep*-tag. Alternative systems may be engineered using protein scaffolds

for generation of novel ligand receptors (see Skerra, 2000, and references therein). These novel binding proteins, e.g. affibodies, may then be useful as fusion partners for different applications (Nygren and Uhlén, 1997; Nord et al., 1997).

5 According to this invention, the said fusion partner should enable dimerization of SSAO. A suitable fusion partner is glutathione S-transferase (GST), because of its propensity to dimerize and because the purification procedure has the potential to be performed under mild conditions using chromatography media with immobilized glutathione (e.g. from Amersham Pharmacia Biotech, Uppsala, Sweden). In addition,

10 GST can conveniently be detected either by its enzymatic activity or by the use of GST specific antibodies or glutathione, using commercially available GST detection systems (e.g. from Amersham Pharmacia Biotech). The fusion partner could also be a functionally equivalent variant of GST, having retained propensity for dimerization and having binding properties allowing affinity purification. The said fusion partner is more

15 preferably a variant of *S. japonicum* GST (GenBank Accession No. M14654; SEQ ID NOS: 3 and 4), designed for secretion out of the host cell, having one or more of the cysteine residues in positions 85, 138, and 178 replaced with other amino acid residue(s). Most preferably, the said variant has all the cysteine residues in positions 85, 138, and 178 replaced with serine residues (see Tudyka & Skerra, 1997 and SEQ ID

20 NO: 5).

In addition, the said recombinant construct should comprise a nucleotide sequence encoding an N-terminal signal peptide, which allows for secretion of the said fusion protein from a host cell into the culture medium. For production of a human protein such as SSAO in a eukaryotic cell a homologous signal peptide is preferred. For production of SSAO in HEK293 cells e.g. a mouse IgG1 heavy chain signal peptide (Kabat et al., 1991) may be used. Other suitable signal peptides are known in the art and are described in e.g. Kabat et al., *supra*.

30 Several methods have been described for site-specific cleavage of fusion proteins based on treatment with chemical agents such as CNBr or hydroxylamine, or enzymes such as enterokinases, Factor Xa, thrombin, subtilisin or other proteases (see e.g. Nilsson et al. (1997) and references therein). According to this invention, the said fusion partner can

conveniently be removed from human SSAO by protease cleavage. The protease to be used for cleavage can e.g. be a 3C protease from the picornavirus family, e.g. a rhinovirus or enterovirus 3C protease (Walker et al., 1994). Consequently, the protease cleavage site can preferably be a cleavage site for a 3C-protease from the picornavirus family, e.g. a rhinovirus or enterovirus 3C protease. In one exemplified form of the invention, the said 3C protease cleavage site comprises the amino acid sequence EALFQG. However, the skilled person will be able to identify other suitable cleavage sites, see e.g. Blom et al. (1996) and references therein.

10 The recombinant construct according to the invention could e.g. comprise a nucleotide sequence encoding essentially the amino acid sequence shown in Figure 1. The invention also provides an expression vector, prepared according to standard methods, comprising the recombinant construct according to the invention. Such an expression vector is exemplified by the expression vector termed pMB887, shown in Figure 3.

15 In another aspect, the invention provides a method for the purification of a recombinant human SSAO polypeptide comprising the steps of:

- (i) transfecting cells with an expression vector according to the invention, as defined above;
- 20 (ii) culturing the said cells under conditions allowing for the fusion protein expressed by the vector to be secreted into the cell medium;
- (iii) binding the obtained fusion protein to a medium comprising a ligand having affinity for the fusion partner;
- (iv) separating the said fusion partner and the SSAO polypeptide; and
- 25 (v) recovering the purified human SSAO polypeptide.

The fusion partner can be separated from the human SSAO variant either when the fusion protein is still attached to the affinity ligand, or when the fusion protein has been released from the affinity ligand. When the said fusion partner is GST, the said ligand having affinity for the fusion partner is preferably glutathione, or a derivative thereof. 30 Alternatively, antibodies directed to GST could be used as affinity ligands.

As mentioned above, the fusion partner can be separated from human SSAO by protease cleavage with e.g. a picornavirus, such as rhinovirus, 3C-protease. The said protease can be fused to a fusion partner, thereby obtaining a "fusion protease" (see Walker et al., 1994; Gräslund et al., 1997). Such a fusion partner can conveniently be the same fusion partner as used for the SSAO polypeptide, e.g. glutathione S-transferase. However, other suitable fusion partners for proteases, such as albumin-binding protein from streptococcal Protein G, are known in the art, see e.g. Gräslund et al., 1997. The said fusion protease can be separated from the SSAO polypeptide by a process comprising binding the fusion protease to a medium comprising a ligand having affinity for the said fusion partner. Consequently, when the fusion partner is GST, the said ligand is preferably glutathione, or a derivative thereof. As mentioned above, antibodies directed to the fusion partner could also be used as affinity ligands. A commercially available system is the PreScission Protease (Amersham Pharmacia Biotech,) which is a genetically engineered fusion protein consisting of *S. japonicum* GST and human rhinovirus 3C protease.

For certain application, it might be advantageous to have SSAO immobilized. This may be achieved e.g. by an affinity-tag such as GST as described above. Examples of applications where a fusion protein is immobilized via an affinity-tag include: capture of protein ligands, analysis of protein-protein interactions, and use in bioreactors (Nilsson et al., 1996; Nord et al., 1997; Shpigel et al., 1999). However, many alternative methods for protein immobilization are described (see e.g. Tischer and Kasche, 1999, and references therein), that also may be applicable for immobilization of GST-SSAO or SSAO after removal of the fusion partner, such as covalent binding and non-covalent adsorption. In addition, the SSAO protein might also be encapsulated in e.g. sol-gel or an artificial cell e.g. a liposome (see e.g. Liang et al., 2000, and references therein). One advantage with an affinity-tag such as GST is that an oriented immobilization can be achieved, often in a one-step procedure directly from e.g. a cell lysate (Nilsson et al., 1997; Saleemuddin, 1999). This may result in good steric accessibility of active binding sites and increased stability (Saleemuddin, 1999; Turkova, 1999). Examples of alternative affinity-tag approaches that has been used for immobilization of proteins are e.g. peptides and proteins that can be specifically biotinylated by biotin ligase and used as fusion partners to take advantage of the very strong interaction ($K_d \sim 10^{-15}$) between

5 biotin and streptavidin or avidin (Nilsson et al., 1997), and CBDs which binds specifically to cellulose (Linder et al., 1998; Tomme et al., 1998). Oriented immobilization of a protein may also be achieved by using immobilized antibodies that binds the protein or through carbohydrate moieties that may be present on the protein surface (Turkova, 1999).

10 Recently, amine oxidase from pea seedlings was immobilized using a modified carbon paste to yield a biosensor for determination of biogenic and synthetic amines (Wimmerova and Macholan, 1999). Similarly, recombinant human SSAO might be immobilized for construction of biosensors to detect e.g. the cardiovascular toxin allylamine which is used in industrial organic processes and is a substrate for SSAO (Boor and Hysmith, 1987; Conklin et al., 1998). When immobilized, recombinant SSAO may be envisioned to mimic a membrane-anchored SSAO and its characteristics, which might differ from the soluble state.

15 Consequently, as shown in the following examples, the invention provides a procedure for the production of a highly purified soluble recombinant human SSAO with enzymatic activity. The exemplified procedure involves the use of a mutant form of *S. japonicum* glutathione *S*-transferase (GST), designed for transport out of the host 20 cells (Tudyka and Skerra, 1997), as an affinity fusion partner. The fusion protein was secreted from mammalian cells and could be purified directly from the culture medium by glutathione-affinity chromatography. By specific proteolysis and an additional glutathione-affinity chromatography step, the fusion partner and the protease were removed, whereby pure, soluble and highly active recombinant human SSAO protein 25 was obtained in milligram quantities. To the inventors' knowledge, this is the first time an active recombinant soluble form of the human SSAO protein has been produced and purified to near homogeneity.

30 It is believed that the disclosed process for production of recombinant human SSAO will be applicable also to other mammalian amine oxidases, such as the human placenta diamine oxidase (Zhang et al., 1995) and the human retina-specific amine oxidase (Imamura et al., 1998), as well as for other secretable proteins. The disclosed process may also facilitate the discovery and identification of modifications e.g. the

identification of the active site cofactor, e.g. by isolation of cofactor-containing peptides or by crystal structure determination.

In the following examples, it is shown that SSAO is active and soluble without its 5 transmembrane region, and that GST can be proteolytically removed. These findings support the hypothesis that SSAO is released into circulation by proteolytic cleavage near the transmembrane region (shedding), a process which is common for Type I and Type II membrane proteins (Hooper et al., 1997). The elevated SSAO activity in plasma in e.g. diabetes (Boomsma et al., 1999) may thus be the consequence of increased 10 proteolytic activity of a protease that cleave the membrane-anchored SSAO, or of increased surface localization increasing the substrate availability for an existing protease.

15 EXPERIMENTAL METHODS

PCR-amplification and cloning of the human SSAO gene from aorta cDNA

Two PCR-primers were designed with the help of the published cDNA sequence of 20 human placenta amine oxidase (GenBank Accession No. U39447; Zhang and McIntire, 1996). The 5'-primer XNQZ-15 (5'-CCG GAA TTC CAA CGC GTC CAT GAA CCA GAA GAC AAT CCT CGT G-3') was designed to hybridize to the 5'- end of the SSAO coding sequence including the ATG start codon and to contain the restriction enzyme cleavage sites *Eco*RI and *Mlu*I for cloning. The 3'-primer XNQZ-17 (5'-CCC CCA 25 AGC TTG TCG ACT CAC TAG TTG TGA GAG AGA AGC CCC CCC-3') was designed to hybridize to the 3'-end including the native stop codon TAG followed by an additional stop codon TGA and two restriction enzyme cleavage sites for cloning, *Sal*II and *Hind*III. As template for the PCR 0.5 μ l human aorta or human smooth muscle cell 30 QUICK-Clone cDNAs (1ng/ μ l, Clontech Laboratories, Palo Alto, CA) were tested. The following conditions was used for the PCR-reaction, 20 pmol of each primer XNQX-15 and XNQZ-17, 1 μ l dNTPs (10 mM), 1 μ l Advantage cDNA Polymerase Mix (Clontech), 5 μ l 10x cDNA PCR reaction buffer (Clontech) in a total volume of 50 μ l.

Amplification was performed with a Perkin-Elmer 2400 thermocycler (Perkin-Elmer, Norwalk, CT). The PCR-program consisted of an initial denaturation at 94°C for 5 min, 35 cycles of 94°C for 30 s, 60°C for 30 s and 72°C for 3 min followed by a final extension at 72°C for 3 min. TA-cloning was then used to insert the PCR-product into the vector pCR2.1-TOPO (Invitrogen, Carlsbad, CA). The cloned PCR-fragment was sequenced in both directions according to a standard protocol for dye terminator cycle sequencing and analyzed on a DNA sequencer ABI 377 (Applied Biosystems, Foster City, CA).

10 *Construction of vectors for expression of SSAO in mammalian cells*

A vector for expression of the complete SSAO protein in mammalian cells was prepared by insertion of the *Eco*RI and *Sal*II fragment from the pCR2.1TOPO-SSAO vector into the same sites of the vector pCI-neo (Promega, Madison, WI), resulting in the vector pMB843. This vector was used as template for PCR-amplification of the region corresponding to residues 29-763 of the human SSAO (Zhang and McIntire, 1996). A 5'-primer 5'- GAG GAA GCT TTG TTC CAA GGT GGA GAT GGG GGT GAA-3' was synthesized containing codons for a partial 3C protease cleavage site (see below) and a *Hind*III restriction enzyme cleavage site upstream of the codon for residue 29. The 3'-primer 5'-GCA TTC TAG TTG TGG TTT GTC-3' is a pCI-neo vector specific primer annealing downstream of the cloned SSAO fragment. The resulting PCR-product was digested with *Hind*III and *Not*I and cloned into the plasmid pET38b(+) (Novagen, Inc., Madison, WI) cut with same enzymes, resulting in pET38-SSAO. DNA sequencing was performed as described above to verify expected sequence of the cloned SSAO fragment.

A mutated form (SEQ ID NO: 5) of the glutathione S-transferase (GST) from *S. japonicum* previously used as a secretable enzymatically active dimerization module for a recombinant protein (Tudyka and Skerra, 1997) was prepared by PCR-mediated mutagenesis and assembly of fragments as described below. The mutations was performed to replace three cysteine residues 85, 138, and 178 located close to the GST protein surface as revealed in the crystal structure of the *S. japonicum* GST (Lim et al., 1994; Tudyka and Skerra, 1997) with serine residues in order to avoid unwanted

disulphide formation after export of the GST fusion protein to an oxidizing environment (Tudyka and Skerra, 1997). The following PCR-primers were used to construct the mutated GST and to introduce the first part of a 3C protease cleavage site (see below) as well as suitable restriction enzyme cleavage sites for cloning. In addition, the primers 5 introduce internal restriction sites for control cleavage and for possibility to assemble PCR-fragments by ligation: ROEL-1 (5'-GCC GGA ATT CGA CGC GTC CCC TAT ACT AGG TTA TTG G-3') contains *Eco*RI and *Mlu*I for cloning and anneals to codons 2-8 of GST (M14654); ROEL-2 (5'-CTC TGC GCG CTC TTT TGG AGA ACC CAA CAT GTT GTG C-3') contains a *Bss*HII site; ROEL-3 (5'-GGT TCT CCA AAA GAG CGC GCA GAG ATT TCA ATG CTT GAA G-3') contains a *Bss*HII site; ROEL-4 (5'- ATG AGA TAA ACG GTC TTC GAA CAT TTT CAG CAT TTC-3') contains a *Bbs*I site; ROEL-5 (5'-GTT CGA AGA CCG TTT ATC TCA TAA AAC ATA TTT AAA TGG TGA TC-3') contains a *Bbs*I site; ROEL-6 (5'-AAA AGA AAC TAG TTT TGG GAA CGC ATC CAG GCA-3') contains a *Spe*I site; ROEL-7 (5'-CCC AAA ACT AGT TTC TTT TAA AAA ACG TAT TGA AGC TAT C-3') contains a *Spe*I site; ROEL-8 (5'-ACC CAA GCT TCC TGA CTT TGT GAC TTT GGA GGA TGG TCG CCA CC-3') contains *Hind*III for cloning and anneals to codons 212-218 of GST (M14654). ROEL-8 will also introduce codons for a spacer-sequence SQSQ before a partial 3C protease cleavage site. Overlapping parts of the GST gene were amplified in 10 separate PCR-reactions with primer pairs ROEL-1/2, ROEL-3/4, ROEL-4/5 and ROEL- 20 7/8, using plasmid pGEX-6P-2 (Amersham Pharmacia Biotech) as template. This allowed the complete mutated GST gene to be assembled by mixing the four PCR- fragments and using them as templates in a PCR reaction with primers ROEL-1 and ROEL- 25 8. The PCR-reactions was performed using the Advantage cDNA PCR Kit (Clontech). In the next step the GST fragment was digested with *Eco*RI and *Hind*III and cloned into the same sites of pUC18 (Amersham Pharmacia Biotech), yielding pMB809. DNA sequencing was performed as described above to confirm the expected 30 sequence of the mutated GST fragment. The pMB809 vector was cleaved with *Eco*RI and *Hind*III and the GST fragment was isolated and cloned upstream of the SSAO fragment in the pET38-SSAO vector cut with the same enzymes. This step resulted in the creation of a complete 3C protease cleavage site EALFQG of human rhinovirus-14 and coxsackievirus (Miyashita et al., 1996; Wang et al., 1997) between GST and SSAO (residues 29-763) (see Fig. 1).

The GST-SSAO fragment was cloned in the *Mlu*I and *Sal*II site of the vector pMB565, in which a mutated signal sequence of a murine IgG1 heavy chain (Fig. 1) is cloned in the multilinker of the mammalian expression vector pCI-neo (Promega). The resulting 5 **GST-SSAO expression vector was named pMB887 (Fig. 3).**

Transfection and selection of stable clones

Three 25 cm² T-flasks were seeded with approximately 4x10⁵ human embryo kidney 10 cells (HEK293 cells, ATCC CRL-1573, Rockville, MD). Cells were grown to ~50% confluence in growth medium containing Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 2 mM L-Glutamine. The FBS was heat-inactivated at 56°C for 30 min before mixed with the growth medium components. The expression vector pMB887 was then introduced into the cells 15 by liposome-mediated transfection using LipofectAMINE according to the manufacturer's recommendations (Life Technologies, Frederick, MD). After 48 hours of growth the medium was changed in all flasks to growth medium supplemented with 1 mg/ml geneticin (G418) for selection of stably transfected cells. Approximately two weeks later, resistant cells emerged and were grown to confluence. Cells from the three 20 T-flasks were pooled (clone-mixture) and diluted in growth medium supplemented with 1.2 mg/ml G418 and seeded in a 15-cm Petri dish. Individual colonies emerged after two weeks and were picked to be expanded individually for subsequent analysis of GST-SSAO production. Detection of GST proteins in collected medium from expanded clones was performed using the GST 96-Well Detection Module (Amersham Pharmacia 25 Biotech). Seven positive clones were selected and frozen.

Production of GST-SSAO in Cell Factories

Clone number 10 was expanded and cultured in growth medium containing DMEM 30 supplemented with 5 % FBS (heat-inactivated), 2 mM L-Glutamine and 1.2 mg/ml G418 and used to seed a 6320 cm² Nunc Cell Factory (Nalge Nunc Int., Naperville, IL) containing 1500 ml of growth medium and grown at 37°C. After four days of growth, cells were confluent and medium was collected. New growth medium (1500 ml) with

reduced amount of FBS (2%) was then added to the cells in the same Cell Factory followed by harvest of conditioned medium after three days. This procedure was repeated once resulting in a total of ~4.5 liters of harvested medium from one Cell Factory. Collected medium was centrifuged and stored at -70°C.

5

Concentration of conditioned cell medium

10 Frozen conditioned medium from two Cell Factories (9.4 liters) was thawed in a water-bath at 30°C. The material was pumped through an Omega membrane (MWCO (Molecular-Weight Cut-Off) 10000) using a Centramate ultra-filtration equipment (Pall Filtron, Northborough, MA), until a volume of 600 ml was achieved. The retentate was filtered through a 0.45 µm filter, Sartobran P, equipped with a 0.65 µm prefilter (Sartorius, Göttingen, Germany). Remaining filtrate in tubings was displaced by 250 ml of phosphate-buffered saline (PBS) yielding 850 ml of filtered sample.

15

Purification and cleavage of GST-SSAO

20 The GST-SSAO fusion protein was purified by glutathione-affinity chromatography on a HR 10/10 column (Amersham Pharmacia Biotech) packed with 8 ml glutathione-Sepharose 4 Fast Flow (Binds ~10 mg GST/ml gel, Amersham Pharmacia Biotech), equilibrated with 10 column volumes of PBS. The filtered material (850 ml), was loaded at 0.9 ml/min over night at room temperature. Flow-through material was collected for analysis and stored at -20°C. After washing the column with PBS, bound proteins were eluted with elution buffer (20 mM GSH, 0.1 M NaCl, 0.1 M Tris-HCl, pH 8.2).

25 The eluate was loaded on a HiPrep Desalt 26/10 column (Amersham Pharmacia Biotech) equilibrated with helium-sparged cleavage-buffer (150 mM NaCl, 1 mM EDTA, 50 mM Tris-HCl, pH 7.5 at 25°C) and the protein peak was collected. Cleavage 30 was started by adding DTT (dithiothreitol) to 5 mM and 380 units of PreScission protease (Amersham Pharmacia Biotech). The PreScission Protease is a genetically engineered fusion protein consisting of GST and human rhinovirus 3C protease and

cleaves specifically between the Gln (Q) and Gly (G) residues of its recognition sequence.

The cleavage mixture was incubated at 5°C. After 63 hours of incubation the material
5 was loaded on a glutathione-Sepharose column as described above, equilibrated with cleavage buffer. The flow-through (36 ml) was collected and stored at 5°C for approximately one week in an open tube. Samples were withdrawn and analyzed by SDS-PAGE (non-reducing). Proteins captured on the column were eluted with elution buffer for analysis. The collected protein sample was applied on a JumboSep device
10 (MWCO 30000, Pall Filtron) for buffer exchange and concentration. Five cycles of centrifugation and dilution with a buffer containing 50 mM Tris-HCl (pH 7.5) and 150 mM NaCl were performed. A sample was taken for different analyses. The buffer exchanged and concentrated material (4.2 ml) was then stored at -70°C.

15 *Protein analyses*

The purification and size of SSAO were analyzed by SDS-PAGE. Samples were electrophoresed in the presence or absence of 2-mercaptoethanol in gradient gels 4-20% or 4-12% (Novex, Copenhagen, Denmark) and proteins were visualized by Coomassie
20 staining (PhastGel Blue R, Amersham Pharmacia Biotech). Protein concentrations were determined with Coomassie Plus protein assay reagent kit (Pierce, Rockford, IL) in 96-well plates with bovine serum albumin as standard according to the manufacturer's procedure.

25 Size exclusion chromatography was performed on a Superdex 200 PC 3.2/30 column (Amersham Pharmacia Biotech) using the SMART System (Amersham Pharmacia Biotech). The column was equilibrated at room temperature with a buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl and 1 mM EDTA. Injection volume was 10 µl and samples were eluted at a flow rate of 0.1 ml/min. For column calibration molecular
30 weight markers Blue Dextran 2000 (~2000 kDa), thyroglobulin (669 kDa), ferritin (440 kDa), catalase (232 kDa) and aldolase (158 kDa) from the Gel Filtration HMW Calibration Kit (Amersham Pharmacia Biotech) was used.

N-terminal sequencing was performed on purified GST-SSAO and SSAO by repeated Edman degradation using a HP G1000A protein sequencer coupled to a HP 1090 PTH analyzer (Hewlett Packard, Palo Alto, CA). The GST-SSAO sample was desalted to remove glutathione prior to analysis. SSAO was taken from the flow-through of the 5 glutathione-Sepharose column after cleavage.

A spectrophotometric assay for monoamine oxidases described by Holt and coworkers (Holt et al., 1997) was used to determine amine oxidase activity in samples from the different purification steps. The assay was performed in 96-well microtiter plates 10 incubated at 37°C in a SPECTRAmax 250 microplate spectrophotometer (Molecular Devices, Sunnyvale, CA). The reagent mix containing 1 mM vanillic acid (Sigma, St. Louis, MO), 500 µM 4-aminoantipyrine (Sigma), and 4U ml⁻¹ peroxidase (type VI from horseradish, Sigma) in 0.2 M potassium phosphate buffer (pH 7.6) was prepared on the same day assays were performed and kept at 5°C until used. Reactions were started by 15 mixing 50 µl sample, 50 µl reagent mix and 200 µl potassium phosphate buffer with or without 750 µM benzylamine hydrochloride (Sigma) and were performed in triplicate. In order to obtain blank reference values, wells were analyzed with buffer added in place of sample. Absorbance changes were followed at 490 nm for 10–40 minutes. Standard curves were prepared with dilutions of a stock solution of H₂O₂ in potassium 20 phosphate buffer ranging from 10 nmol/well to 120 nmol/well. When inhibition experiments were carried out, the samples were incubated in 300 µM semicarbazide at 37°C for 30 minutes, before addition of the benzylamine solution.

25 EXAMPLES

EXAMPLE 1: Cloning of SSAO cDNA

A PCR-strategy was used to amplify the gene of a human SSAO from human aorta 30 cDNA. The PCR-primers were designed to include sequences flanking the human placenta amine oxidase gene (Zhang and McIntire, 1996) and to include restriction enzyme cleavage sites for cloning into different expression vectors. The ~2300 bp PCR-product was cloned and subsequent DNA-sequencing showed that the sequence of the

cloned PCR-product was identical to the human placenta amine oxidase sequence (Zhang and McIntire, 1996) and to the VAP-1 sequence cloned from lung cDNA (Smith et al., 1998).

5

EXAMPLE 2: Purification of membrane-bound SSAO (Example for comparison)

Attempts to produce a recombinant SSAO protein showed that active SSAO could be produced in human embryo kidney (HEK293) cells using the pMB843 vector in which 10 the entire coding sequence of human SSAO was cloned. Active protein was found after extraction using solubilizing agents, but only microgram amounts of protein could be partially purified.

15 **EXAMPLE 3: Rationale and design of a gene construct for expression of a soluble form of SSAO**

An alternative strategy was developed for production of a non-membrane-bound SSAO in mammalian cells. Purification and detection were performed by replacing the N- 20 terminal region containing the putative membrane spanning peptide with an affinity fusion partner having an inherent dimerization propensity. The strategy also involved the use of a secretable affinity fusion partner to be able to secrete the fusion protein into the culture medium. A mutated variant of *S. japonicum* glutathione S-transferase (GST) was selected. This mutant GST retains its activity as well as its propensity to dimerize 25 and have been optimized for secretion (Tudyka and Skerra, 1997).

A protease cleavage site was designed to enable release of SSAO from the purified GST-SSAO fusion protein. Scanning of the predicted amino acid sequence revealed an arginine at position 28 flanked by three glycine residues. Several human proteases 30 cleave after basic residues (Carter, 1990; Hooper et al., 1997) and short stretches of glycine residues have been suggested to enhance accessibility to proteases (Carter, 1990). In addition, the proteolytic release of the extracellular region (shedding) of many membrane-anchored proteins into the blood stream occurs close to the membrane

(Hooper et al., 1997). The glycine residue at position 29 was therefore chosen to be linked to a suitable substrate for site-specific proteolysis after purification of the GST-SSAO fusion protein. Thus, a protease that can cleave a substrate having a glycine in the P1' position and having high specificity was desired. Several commercial proteases 5 exist having these two properties such as factor Xa, thrombin, enterokinase and 3C protease (Nilsson et al., 1997). The ability to easily capture the protease after cleavage was another factor considered, leading to the selection of a commercially available 3C protease fused to GST. The 3C protease cleavage site EALFQG (Miyashita et al., 1996; Wang et al., 1997) was introduced in the GST-SSAO fusion construct (Fig. 1).

10 The GST-SSAO fragment was cloned in frame with a signal sequence to achieve secretion of the GST-SSAO fusion protein into the culture medium. A signal sequence derived from the heavy chain of a murine antibody was used (see Fig. 1). The final construct thus encoded a fusion protein comprising of an antibody signal peptide, an 18 15 amino acid spacer region, the mutated GST protein, a substrate sequence for the 3C protease and residues 29-763 of the human SSAO protein cloned from human aorta cDNA (Fig. 1). The calculated molecular weight of the unmodified GST-SSAO fusion protein is 112 kDa.

20 EXAMPLE 4: Initial analyses on conditioned medium from HEK293 cells transfected with the GST-SSAO expression vector

25 Benzylamine oxidase activity in the conditioned medium from small-scale cultures of HEK293 cells, stably transfected with the GST-SSAO expression vector pMB887, indicated that GST-SSAO was secreted into the culture medium. Further analyses showed that glutathione-Sepharose beads could be used to purify small amounts of the GST-SSAO fusion protein directly from the conditioned medium (data not shown), and that the purified material had benzylamine oxidase activity. Interestingly, the GST- 30 SSAO fusion protein was found to be active also when immobilized on the glutathione-Sepharose beads. The amount of GST-SSAO fusion protein in the conditioned medium was calculated to be ~1 mg/l, by estimation of the amount of protein captured on the beads.

EXAMPLE 5: Preparative purification and site-specific cleavage of the GST-SSAO fusion protein

5

An overview of the affinity purification based procedure is shown in Fig. 2. The results of the purification are summarized in Table 1. One selected clone was expanded and grown in Cell Factories to generate larger amounts of GST-SSAO for purification. The harvested conditioned medium were concentrated and filtrated to reduce the time for 10 loading on the glutathione-Sepharose column. Glutathione-affinity chromatography was then applied to purify the GST-SSAO fusion protein from the concentrated and filtered conditioned medium. Proteins captured on the column were eluted with 20 mM GSH and analyzed by SDS-PAGE under reducing conditions. This showed that the GST-SSAO fusion protein had high purity and that it could be isolated from large amounts of 15 other proteins in the culture medium in a single step. The GST-SSAO fusion protein migrated in level with the 116 kDa protein in the molecular weight marker. In total 8.8 mg of protein was recovered from the glutathione-Sepharose column. The specific activity of the GST-SSAO fusion protein was determined to $343 \text{ nmol} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$. Interestingly, the specific activity was almost doubled ($634 \text{ nmol} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$) by the 20 buffer exchange step which removed the reducing agent GSH.

25

The glutathione-affinity purified GST-SSAO was cleaved with the GST-3C protease fusion protein (46 kDa) to remove the GST fusion partner from SSAO. Analytical experiments suggested that cleavage was slow, but precise, with no observable side-products. Moreover, complete cleavage could be obtained after ~48 hours incubation. The cleavage mixture was passed over the glutathione-Sepharose column to capture the removed GST fusion partner and the GST-3C protease. Flow-through material was collected and analyzed by SDS-PAGE under reducing conditions which showed only the expected SSAO product with a molecular weight of ~97 kDa. Captured material was 30 also analyzed, which showed only the GST fusion partner (~28 kDa) and the GST-3C protease. This indicated that a complete cleavage had occurred and all GST containing proteins had been captured on the glutathione-Sepharose column. It also indicated that

all SSAO protein had passed through the column since no SSAO protein was seen in the eluted material.

The specific activity of the purified SSAO protein was determined to $522 \text{ nmol} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$ which was less than the specific activity determined before cleavage. Since DTT had been used to ensure 3C protease activity during cleavage of the GST-SSAO fusion protein, we made an SDS-PAGE analysis (non-reducing) to see if the cleavage buffer had affected possible disulphide bridges in the SSAO homodimer (Kurkijärvi et al., 1998; Smith et al., 1998; Salminen et al., 1998). Only presumed SSAO monomers (~97 kDa) could be seen (data not shown). However, the SSAO protein was transformed to ~170 kDa in size (analyzed by SDS-PAGE) during storage at 5°C, indicating that one or several disulphides were formed. The cleavage buffer was removed by diafiltration and SDS-PAGE analysis showed that the SSAO protein was still apparently dimeric with a molecular weight of ~170 kDa. In total 3.6 mg of recombinant SSAO was obtained from 9.4 liters of conditioned medium having a specific activity of $809 \text{ nmol} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$. The overall yield in the process was 22 % based on determined benzylamine oxidase activity.

Interestingly, the GST fusion partner did not significantly affect the benzylamine oxidase activity of the SSAO protein. The specific activity of the purified GST-SSAO fusion protein after the buffer exchange step, was determined to $634 \text{ nmol} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$. After removal of the GST fusion partner, the specific activity of SSAO was determined to $809 \text{ nmol} \cdot \text{min}^{-1} \cdot \text{mg}^{-1}$. However, the molecular mass of the GST fusion partner is ~25 % of the GST-SSAO fusion protein and the increase in specific activity after removal of GST was in the same range. This opens up possibilities to use the fusion protein for enzyme characterization. Furthermore, an affinity fusion partner such as GST can be used to bind or immobilize a recombinant protein in a directed manner on solid supports to study e.g. protein-protein interactions and enzyme characteristics (Nilsson et al., 1997). The GST-SSAO fusion protein was indeed active when it was bound to glutathione-Sepharose beads.

EXAMPLE 6: Initial characterization of purified SSAO proteins

5 A gel filtration experiment was performed to analyze the size of the SSAO protein under non-denaturing conditions. A sample from the SSAO protein material that migrated as a dimeric protein when investigated by SDS-PAGE under non-reducing conditions was loaded on a calibrated analytical Superdex 200 column. The SSAO protein eluted at 1.29 ml, which was slightly faster than catalase (232 kDa), which
10 eluted at 1.35 ml.

15 N-terminal amino acid sequencing of the purified SSAO protein showed that the GST-3C protease had specifically cleaved the 3C protease substrate sequence EALFQG in the GST-SSAO fusion protein (Fig. 1). Twenty-nine amino acids were determined and corresponded exactly to residues number 29-58 in the predicted SSAO amino acid sequence (SEQ ID NO: 2). N-terminal sequencing was also performed on the GST-SSAO fusion protein, which showed that the signal peptide had been processed as anticipated.

20 Finally, the purified SSAO protein was found to be sensitive to inhibition by semicarbazide as expected. In the presence of 0.1 mM semicarbazide more than 95 % of the benzylamine oxidase activity was inhibited.

TABLE I
Purification of recombinant human SSAO

Purification step (sample)	Total volume (ml)	Total protein (mg)	Total SSAO activity ^a (nmol min ⁻¹)	Specific activity (nmol min ⁻¹ mg ⁻¹)	Yield (%)
Conditioned medium	9400	9024	9243	1.0	—
Concentrated medium	600	9060	13200	1.5	100
Filtrate	850	9065	11900	1.3	90
GSH-affinity step-1 (eluate)	6.8	8.8	3029	343	23
Buffer exchange	15	8.9	5624 ^b	634 ^b	43
GSH-affinity step-2 (flow-through) ^c	36	5.5	2859	522	22
Diafiltrate ^d	4.2	3.6	2919	809	22

^aActivity was measured as nmol of H₂O₂ produced per minute using 0.5 mM benzylamine as substrate. SSAO activity was confirmed with 0.1 mM semicarbazide as inhibitor.

^bMeasured before addition of 5 mM DTT and GST-3C protease.

^cThis step was performed after site-specific cleavage of the GST-SSAO fusion protein to capture removed GST fusion partner and GST-3C protease.

^dBuffer exchange and sample concentration by ultra-filtration.

REFERENCES

Blom, N., Hansen, J., Blaas, D. and Brunak, S. (1996) Cleavage site analysis in picornaviral polyproteins: Discovering cellular targets by neural networks. *Protein Science* 5, 2203-2216.

Boomsma, F., van Veldhuisen, D. J., de Kam, P. J., Man in't Veld, A. J., Mosterd, A., Lie, K. I., and Schalekamp, M. A. (1997) Plasma semicarbazide-sensitive amine oxidase is elevated in patients with congestive heart failure. *Cardiovasc. Res.* 33(2), 387-391.

Boomsma, F., van den Meiracker, A. H., Winkel, S., Aanstoot, H. J., Batstra, M. R., Man in 't Veld, A. J., and Bruining, G. J. (1999) Circulating semicarbazide-sensitive amine oxidase is raised both in type I (insulin-dependent), in type II (non-insulin-dependent) diabetes mellitus and even in childhood type I diabetes at first clinical diagnosis. *Diabetologia* 42(2), 233-237.

Boor, P. J., and Hysmith, R. M. (1987) Allylamine cardiovascular toxicity. *Toxicology* 44(2), 129-145.

Buffoni, F. (1993) Properties, distribution and physiological role of semicarbazide-sensitive amine oxidases. *Curr. Top. Pharmacol.* 2, 33-49.

Callingham, B. A., Crosbie, A. E., and Rous, B. A. (1995) Some aspects of the pathophysiology of semicarbazide-sensitive amine oxidase enzymes. *Prog. Brain Res.* 106, 305-321.

Carter, P. (1990) Site-specific proteolysis of fusion proteins. In *Protein purification: From molecular mechanism to large-scale processes* (Am. Chem. Soc. Symp. Ser. No. 427) (Ladish, M. R., Willson, R. C., Painton, C. C., and Builder, S. E., eds), pp. 181-193, American Chemical Society Press.

Castillo, V., Lizcano, J. M., Visa J., and Unzeta, M. (1998) Semicarbazide-sensitive amine oxidase (SSAO) from human and bovine cerebrovascular tissues: biochemical and immunohistological characterization. *Neurochem. Int.* 33(5), 415-423.

5 Conklin, D. J., Langford, S. D., and Boor, P. J. (1998) Contribution of serum and cellular semicarbazide-sensitive amine oxidase to amine metabolism and cardiovascular toxicity. *Toxicol. Sci.* 46(2), 386-392.

Dwyer, M. A., Huang, A. J., Pan, C. Q., and Lazarus, R. A. Expression and 10 characterization of a DNase I-Fc fusion enzyme. (1999) *J. Biol. Chem.* 274(14), 9738-9743.

Ekblom, J. (1998) Potential therapeutic value of drugs inhibiting semicarbazide-sensitive amine oxidase: vascular cytoprotection in diabetes mellitus. *Pharmacol. Res.* 15 37(2), 87-92.

Gräslund, T., Nilsson, J., Lindberg, A. M., Uhlén, M., and Nygren, P. Å. (1997) Production of a thermostable DNA polymerase by site-specific cleavage of a heat-eluted affinity fusion protein. *Protein Expression Purif.* 9(1), 125-132.

20 Hartmann, C., and McIntire, W. S. (1997) Amine-oxidizing quinoproteins. *Methods Enzymol.* 280, 98-150.

Hollenbaugh, D., Chalupny, N. J., and Aruffo, A. (1992) Recombinant globulins: novel 25 research tools and possible pharmaceuticals. *Curr. Opin. Immunol.* 4(2), 216-219.

Holt, A., Sharman, D. F., Baker, G. B., and Palcic, M. M. (1997) A continuous spectrophotometric assay for monoamine oxidase and related enzymes in tissue homogenates. *Anal. Biochem.* 244(2), 384-392.

30 Holt, A., Alton, G., Scaman, C. H., Loppnow, G. R., Szpacenko, A., Svendsen, I., and Palcic, M. M. (1998) Identification of the quinone cofactor in mammalian semicarbazide-sensitive amine oxidase. *Biochemistry* 37(14), 4946-4957.

Hooper, N. M., Karran, E. H., and Turner, A. J. (1997) Membrane protein secretases. *Biochem J.* 321(Pt 2), 265-279.

5 Imamura, Y., Noda, S., Mashima, Y., Kudoh, J., Oguchi, Y., and Shimizu, N. (1998) Human retina-specific amine oxidase: genomic structure of the gene (AOC2), alternatively spliced variant, and mRNA expression in retina. *Genomics* 51(2), 293-298.

10 Jaakkola, K., Kaunismaki, K., Tohka, S., Yegutkin, G., Vanttila, E., Havia, T., Pelliniemi, L. J., Virolainen, M., Jalkanen, S., and Salmi, M. (1999) Human vascular adhesion protein-1 in smooth muscle cells. *Am. J. Pathol.* 155(6), 1953-1965.

15 Kabat, E. A., Wu, T. T., Perry, H. M., Gottesman, K. S., and Foeller, C. (1991) Sequences of proteins of immunological interest. (U.S. Department of Health and Human Services; Public Health Service National Institutes of Health) NIH Publication No. 91-3242.

20 Kurkijärvi, R., Adams D. H., Leino R., Mottonen T., Jalkanen S., and Salmi, M. (1998) Circulating form of human vascular adhesion protein-1 (VAP-1): Increased serum levels in inflammatory liver diseases. *J. Immunol.* 161, 1549-1557.

25 Larsson, L. N., Johansson, C., Lindholm, L., and Holmgren, J. (1988) Mouse monoclonal antibodies for experimental immunotherapy promotes killing of tumor cells. *Int. J. Cancer* 42, 877-882.

30 Lewinsohn, R. (1984) Mammalian monoamine-oxidizing enzymes, with special reference to benzylamine oxidase in human tissues. *Braz. J. Med. Biol. Res.* 17(3-4), 223-256.

30 Liang, J. F., Li, Y. T., and Yang, V. C. (2000) Biomedical application of immobilized enzymes. *J. Pharm. Sci.* 89(8), 979-990.

Linder, M., Nevanen, T., Söderholm, L., Bengs, O., and Teeri, T. T. (1998) Improved immobilization of fusion proteins via cellulose-binding domains. *Biotechnol. Bioeng.* 60(5), 642-647.

5 Lim, K., Ho, J. X., Keeling, K., Gilliland, G. L., Ji, X., Ruker, F., and Carter, D. C. (1994) Three-dimensional structure of *Schistosoma japonicum* glutathion S-transferase fused with a six-amino acid conserved neutralizing epitope of gp41 from HIV. *Protein Sci.* 3(12), 2233-2244.

10 Lo, K. M., Sudo, Y., Chen, J., Li, Y., Lan, Y., Kong, S. M., Chen, L., An, Q., and Gillies, S. D. (1998) High level expression and secretion of Fc-X fusion proteins in mammalian cells. *Protein Eng.* 11(6), 495-500.

15 Lyles, G. A. (1996) Mammalian plasma and tissue-bound semicarbazide-sensitive amine oxidases: biochemical, pharmacological and toxicological aspects. *Int. J. Biochem. Cell Biol.* 28(3), 259-274.

20 Lyles, G. A., and Pino, R. (1998) Properties and functions of tissue-bound semicarbazide-sensitive amine oxidases in isolated cell preparations and cell cultures. *J. Neural. Transm. Suppl.* 52, 239-250.

25 Meszaros, Z., Karadi, I., Csanyi, A., Szombathy, T., Romics, L., and Magyar, K. (1999) Determination of human serum semicarbazide-sensitive amine oxidase activity: a possible clinical marker of atherosclerosis. *Eur. J. Drug Metab. Pharmacokinet.* 24(4), 299-302.

30 Miyashita, K., Okunishi, J., Utsumi, R., Komano, T., Tamura, T., and Satoh, N. (1996) Cleavage specificity of coxsackievirus 3C proteinase for peptide substrate. *Biosci. Biotechnol. Biochem.* 60(4), 705-707.

Morris, N. J., Ducret, A., Aebersold, R., Ross, S. A., Keller, S.R., and Lienhard, G. E. (1997) Membrane amine oxidase cloning and identification as a major protein in the adipocyte plasma membrane. *J. Biol. Chem.* 272, 9388-9392.

Müller, K. M., Arndt, K. M., and Alber, T. (2000) Protein fusions to coiled-coil domains. *Methods Enzymol.* 328, 261-282.

5 Nakos, G., and Gossrau, R. (1994) Light microscopic visualization of semicarbazide-sensitive amine oxidase (benzylamine oxidase) using a cerium method. *Folia Histochem. Cytobiol.* 32(1), 3-10.

10 Nilsson, J., Larsson, M., Ståhl, S., Nygren, P. Å., and Uhlén, M. (1996) Multiple affinity domains for the detection, purification and immobilization of recombinant proteins. *J. Mol. Recognit.* 9(5-6), 585-594.

15 Nilsson, J., Ståhl S., Lundeberg J., Uhlén M., and Nygren, P. Å. (1997) Affinity fusion strategies for detection, purification and immobilization of recombinant proteins. *Protein Expression Purif.* 11, 1-16.

20 Nord, K., Gunneriusson, E., Ringdahl, J., Ståhl, S., Uhlén, M., and Nygren, P. Å. (1997) Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. *Nat. Biotechnol.* 15(8), 772-777.

Nygren, P. Å., and Uhlén, M. (1997) Scaffolds for engineering novel binding sites in proteins. *Curr. Opin. Struct. Biol.* 7(4), 463-469.

25 Rieker, J. D., and Hu, J. C. (2000) Molecular applications of fusions to leucine zippers. *Methods Enzymol.* 328, 282-296.

30 Sakurai, T., Roonprapunt, C., and Grumet, M. (1998) Purification of Ig-fusion proteins from medium containing Ig. *Biotechniques* 25(3), 382-385.

Saleemuddin M (1999) Bioaffinity based immobilization of enzymes. *Adv. Biochem. Eng. Biotechnol.* 64, 203-226.

35 Salminen, T. A., Smith, D. J., Jalkanen, S., and Johnson, M. S. (1998) Structural model

of the catalytic domain of an enzyme with cell adhesion activity: human vascular adhesion protein-1 (HVAP-1) D4 domain is an amine oxidase. *Protein Eng.* 11(12), 1195-204.

5 Sheibani, N. (1999) Prokaryotic gene fusion expression systems and their use in structural and functional studies of proteins. *Prep. Biochem. & Biotechnol.* 29, 77-90.

10 Shpigel, E., Goldlust, A., Efroni, G., Avraham, A., Eshel, A., Dekel, M., and Shoseyov, O. (1999) Immobilization of recombinant heparinase I fused to cellulose-binding domain. *Biotechnol. Bioeng.* 65(1), 17-23.

15 Skerra, A. (2000) Engineered protein scaffolds for molecular recognition. *J. Mol. Recognit.* 13(4), 167-187.

15 Smith, D.B. and Johnson, K.S. (1988) Single-step purification of polypeptides expressed in *Escherichia coli* as fusions with glutathione S-transferase. *Gene* 67, 31-40.

20 Smith, D. J., Salmi, M., Bono, P., Hellman, J., Leu, T., and Jalkanen, S. (1998) Cloning of vascular adhesion protein 1 reveals a novel multifunctional adhesion molecule. *J. Exp. Med.* 188, 17-27.

Tischer, W., and Kasche, V. (1999) Immobilized enzymes: crystals or carriers? *Trends Biotechnol.* 17(8), 326-335.

25 Tomme, P., Boraston, A., McLean, B., Kormos, J., Creagh, A. L., Sturch, K., Gilkes, N. R., Haynes, C. A., Warren, R. A., and Kilburn, D. G. (1998) Characterization and affinity applications of cellulose-binding domains. *J. Chromatogr. B Biomed. Sci. Appl.* 715(1), 283-296.

30 Tudyka, T., and Skerra, A. (1997) Glutathione S-transferase can be used as a C-terminal enzymatically active dimerization module for a recombinant protease inhibitor, and functionally secreted into the periplasm of *Escherichia coli*. *Protein Sci.* 6, 2180-2187.

Turkova, J. (1999) Oriented immobilization of biologically active proteins as a tool for revealing protein interactions and function. *J. Chromatogr. B Biomed. Sci. Appl.* 722(1-2), 11-31.

5 Uhlén, M., Forsberg, G., Moks T., Hartmanis, M., and Nilsson, B. (1992) Fusion proteins in Biotechnology. *Curr. Opin. Biotechnol.* 3, 363-369.

Wang, Q. M., Johnson, R. B., Cox, G. A., Villarreal, E. C., and Loncharich, R. J. (1997) A continuous colorimetric assay for rhinovirus-14 3C protease using peptide p-nitroanilides as substrates. *Anal. Biochem.* 252(2), 238-245.

10 Walker, P.A., Leong, L. E., Ng, P. W., Tan, S. H., Waller, S., Murphy, D., and Porter, A. G. (1994) Efficient and rapid affinity purification of proteins using recombinant fusion proteases. *Bio/Technology* 12, 601-605.

15 Wimmerova, M., and Macholan, L. (1999) Sensitive amperometric biosensor for the determination of biogenic and synthetic amines using pea seedlings amine oxidase: a novel approach for enzyme immobilisation. *Biosens. Bioelectron.* 14(8-9), 695-702.

20 Yu, P. H. and Zuo, D. M. (1993) Oxidative deamination of methylamine by semicarbazide-sensitive amine oxidase leads to cytotoxic damage in endothelial cells. Possible consequences for diabetes. *Diabetes* 42(4), 594-603.

25 Yu, P. H., Zuo, D. M., and Davis, B. A. (1994) Characterization of human serum and umbilical artery semicarbazide-sensitive amine oxidase (SSAO). Species heterogeneity and stereoisomeric specificity. *Biochem. Pharmacol.* 47(6), 1055-1059.

Zhang, X., Kim, J., and McIntire, W. S. (1995) cDNA sequences of variant forms of human placenta diamine oxidase. *Biochem. Genet.* 33(7-8), 261-268.

30 Zhang, X and McIntire, W. S. (1996) Cloning and sequencing of a copper-containing, topa quinone-containing monoamine oxidase from human placenta. *Gene* 179, 279-286.

CLAIMS

1. A recombinant construct comprising a nucleotide sequence encoding a fusion protein comprising
 - 5 (i) a soluble form of human SSAO;
 - (ii) a secretable fusion partner enabling dimerization of SSAO;
 - (iii) a signal peptide allowing for secretion of a polypeptide from a host cell into the culture medium; and
 - (iv) a protease cleavage site located between the human SSAO variant and the
- 10 fusion partner.
2. The method according to claim 1 wherein the said soluble form of human SSAO is lacking the membrane spanning portion essentially shown as amino acids 6 to 26 in SEQ ID NO: 2.
- 15 3. The method according to claim 2 wherein the said soluble form of human SSAO essentially consists of amino acids 29 to 763 of SEQ ID NO: 2.
4. The recombinant construct according to any one of claims 1 to 3, encoding a fusion protein wherein the said fusion partner is fused to the N-terminal portion of the human SSAO polypeptide.
- 20 5. The recombinant construct according to any one of claims 1 to 4 wherein the said fusion partner is glutathione S-transferase or a functionally equivalent variant thereof.
- 25 6. The recombinant construct according to claim 5 wherein the said fusion partner is a variant of *Schistosoma japonicum* glutathione S-transferase, said variant having at least one of the cysteine residues in positions 85, 138, and 178 replaced by another amino acid residue.
- 30 7. The recombinant construct according to any one of claims 1 to 6 wherein the said signal peptide is a mouse IgG1 heavy chain signal peptide.

8. The recombinant construct according to any one of claims 1 to 7 wherein the said protease cleavage site is a 3C protease cleavage site.
- 5 9. The recombinant construct according to claim 8 wherein the said 3C protease cleavage site comprises the amino acid sequence EALFQG.
- 10 10. The recombinant construct according to any one of claims 1 to 9 comprising nucleotide sequence encoding essentially the amino acid sequence shown in Figure 1.
11. An expression vector comprising the recombinant construct according to any one of claims 1 to 10.
- 15 12. The expression vector according to claim 11, which is the expression vector termed pMB887, shown in Figure 3.
13. A method for the purification of a recombinant human SSAO polypeptide comprising the steps of:
 - 20 (i) transfecting cells with an expression vector according to claim 11;
 - (ii) culturing the said cells under conditions allowing for the fusion protein expressed by the vector to be secreted into the culture medium;
 - (iii) binding the obtained fusion protein to a medium comprising a ligand having affinity for the fusion partner;
 - 25 (iv) separating the said fusion partner and the SSAO polypeptide; and
 - (v) recovering the purified human SSAO polypeptide.
14. The method according to claim 13 wherein the said ligand having affinity for the fusion partner is glutathione, or a derivative thereof.
- 30 15. The method according to claim 13 or 14 wherein the said fusion partner is separated from human SSAO in step (iv) by protease cleavage.

16. The method according to claim 15 wherein the said protease is a picornavirus 3C-protease.
17. The method according to claim 16 wherein the said protease is rhinovirus 3C-protease.
5
18. The method according to claim 16 or 17 wherein the said protease is fused to a fusion partner, thereby obtaining a "fusion protease".
- 10 19. The method according to claim 18 wherein the said fusion protease is separated from the SSAO polypeptide by a process comprising binding the said fusion protease to a medium comprising a ligand having affinity for the said fusion protease.
- 15 20. A method for the preparation of an immobilized recombinant human SSAO polypeptide comprising the steps of:
 - (i) transfecting cells with an expression vector according to claim 11;
 - (ii) culturing the said cells under conditions allowing for the fusion protein expressed by the vector to be secreted into the culture medium;
 - 20 (iii) binding the obtained fusion protein to a medium comprising a ligand having affinity for the fusion partner.
21. An immobilized recombinant human SSAO polypeptide obtainable by the method as defined in claim 20.
- 25 22. An immobilized or encapsulated recombinant human SSAO polypeptide obtainable by the method as defined in claim 13.

ABSTRACT

The present invention relates to a recombinant construct comprising a nucleotide sequence encoding a fusion protein comprising a soluble form of human SSAO (Semicarbazide-Sensitive Amine Oxidase), a secretable fusion partner, a signal peptide; and a protease cleavage site. The said construct is useful in methods for purification of a soluble form of human SSAO.

20
19
18
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1

- 1 -

SEQUENCE LISTING

<110> Pharmacia AB
<120> Methods for Protein Purification
<130> 00395
<160> 5
<170> PatentIn version 3.0
<210> 1
<211> 4040
<212> DNA
<213> human

<220>
<221> CDS
<222> (161)...(2452)

<300>
<308> GenBank/NM_003734
<309> 2000-01-28

<300>
<308> GenBank/U39447
<309> 1997-01-08

<400> 1
gtccttcca cccttagtcc caggcatctg actaccggga acctcagcca gagtccggga 60
gccccccacc ccgtccagga gccaacagag ccccgcttt gctggcgtga gaatacattt 120
ctctcccttg gttgaatcag ctgtccctct tcgtggaaa atg aac cag aag aca 175
Met Asn Gln Lys Thr
1 5

atc ctc gtg ctc ctc att ctg gcc gtc atc acc atc ttt gcc ttg gtt 223
Ile Leu Val Leu Leu Ile Leu Ala Val Ile Thr Ile Phe Ala Leu Val
10 15 20

tgt gtc ctg ctg gtg ggc agg ggt gga gat ggg ggt gaa ccc agc cag 271
Cys Val Leu Leu Val Gly Arg Gly Gly Asp Gly Glu Pro Ser Gln
25 30 35

ctt ccc cat tgc ccc tct gta tct ccc agt gcc cag cct tgg aca cac 319
Leu Pro His Cys Pro Ser Val Ser Pro Ser Ala Gln Pro Trp Thr His
40 45 50

cct ggc cag agc cag ctg ttt gca gac ctg agc cga gag gag ctg acg 367
Pro Gly Gln Ser Gln Leu Phe Ala Asp Leu Ser Arg Glu Glu Leu Thr
55 60 65

- 2 -

gct gtg atg cgc ttt ctg acc cag cgg ctg ggg cca ggg ctg gtg gat	415
Ala Val Met Arg Phe Leu Thr Gln Arg Leu Gly Pro Gly Leu Val Asp	
70 75 80 85	
gca gcc cag gcc cgg ccc tcg gac aac tgt gtc ttc tca gtg gag ttg	463
Ala Ala Gln Ala Arg Pro Ser Asp Asn Cys Val Phe Ser Val Glu Leu	
90 95 100	
cag ctg cct ccc aag gct gca gcc ctg gct cac ttg gac agg ggg agc	511
Gln Leu Pro Pro Lys Ala Ala Leu Ala His Leu Asp Arg Gly Ser	
105 110 115	
ccc cca cct gcc cgg gag gca ctg gcc atc gtc ttc ttt ggc agg caa	559
Pro Pro Pro Ala Arg Glu Ala Leu Ala Ile Val Phe Phe Gly Arg Gln	
120 125 130	
ccc cag ccc aac gtg agt gag ctg gtg ggg cca ctg cct cac ccc	607
Pro Gln Pro Asn Val Ser Glu Leu Val Val Gly Pro Leu Pro His Pro	
135 140 145	
tcc tac atg cgg gac gtg act gtg gag cgt cat gga ggc ccc ctg ccc	655
Ser Tyr Met Arg Asp Val Thr Val Glu Arg His Gly Gly Pro Leu Pro	
150 155 160 165	
tat cac cga cgc ccc gtg ctg ttc caa gag tac ctg gac ata gac cag	703
Tyr His Arg Arg Pro Val Leu Phe Gln Glu Tyr Leu Asp Ile Asp Gln	
170 175 180	
atg atc ttc aac aga gag ctg ccc cag gct tct ggg ctt ctc cac cac	751
Met Ile Phe Asn Arg Glu Leu Pro Gln Ala Ser Gly Leu Leu His His	
185 190 195	
tgt tgc ttc tac aag cac cgg gga cgg aac ctg gtg aca atg acc acg	799
Cys Cys Phe Tyr Lys His Arg Gly Arg Asn Leu Val Thr Met Thr Thr	
200 205 210	
gct ccc cgt ggt ctg caa tca ggg gac cgg gcc acc tgg ttt ggc ctc	847
Ala Pro Arg Gly Leu Gln Ser Gly Asp Arg Ala Thr Trp Phe Gly Leu	
215 220 225	
tac tac aac atc tcg ggc gct ggg ttc ctg cac cac gtg ggc ttg	895
Tyr Tyr Asn Ile Ser Gly Ala Gly Phe Phe Leu His His Val Gly Leu	
230 235 240 245	
gag ctg cta gtg aac cac aag gcc ctt gac cct gcc cgc tgg act atc	943
Glu Leu Leu Val Asn His Lys Ala Leu Asp Pro Ala Arg Trp Thr Ile	
250 255 260	
cag aag gtg ttc tat caa ggc cgc tac tac gac agc ctg gcc cag ctg	991
Gln Lys Val Phe Tyr Gln Gly Arg Tyr Tyr Asp Ser Leu Ala Gln Leu	
265 270 275	
gag gcc cag ttt gag gcc ggc ctg gtg aat gtg gtg ctg atc cca gac	1039
Glu Ala Gln Phe Glu Ala Gly Leu Val Asn Val Val Leu Ile Pro Asp	
280 285 290	

- 3 -

aat ggc aca ggt ggg tcc tgg tcc ctg aag tcc cct gtg ccc ccg ggt Asn Gly Thr Gly Gly Ser Trp Ser Leu Lys Ser Pro Val Pro Pro Gly 295 300 305	1087
cca gct ccc cct cta cag ttc tat ccc caa ggc ccc cgc ttc agt gtc Pro Ala Pro Pro Leu Gln Phe Tyr Pro Gln Gly Pro Arg Phe Ser Val 310 315 320 325	1135
cag gga agt cga gtg gcc tcc tca ctg tgg act ttc tcc ttt ggc ctc Gln Gly Ser Arg Val Ala Ser Ser Leu Trp Thr Phe Ser Phe Gly Leu 330 335 340	1183
gga gca ttc agt ggc cca agg atc ttt gac gtt cgc ttc caa gga gaa Gly Ala Phe Ser Gly Pro Arg Ile Phe Asp Val Arg Phe Gln Gly Glu 345 350 355	1231
aga cta gtt tat gag ata agc ctc caa gag gcc ttg gcc atc tat ggt Arg Leu Val Tyr Glu Ile Ser Leu Gln Glu Ala Leu Ala Ile Tyr Gly 360 365 370	1279
gga aat tcc cca gca gca atg acg acc cgc tat gtg gat gga ggc ttt Gly Asn Ser Pro Ala Ala Met Thr Thr Arg Tyr Val Asp Gly Gly Phe 375 380 385	1327
ggc atg ggc aag tac acc acg ccc ctg acc cgt ggg gtg gac tgc ccc Gly Met Gly Lys Tyr Thr Pro Leu Thr Arg Gly Val Asp Cys Pro 390 395 400 405	1375
tac ttg gcc acc tac gtg gac tgg cac ttc ctt ttg gag tcc cag gcc Tyr Leu Ala Thr Tyr Val Asp Trp His Phe Leu Leu Glu Ser Gln Ala 410 415 420	1423
ccc aag aca ata cgt gat gcc ttt tgt gtg ttt gaa cag aac cag ggc Pro Lys Thr Ile Arg Asp Ala Phe Cys Val Phe Glu Gln Asn Gln Gly 425 430 435	1471
ctc ccc ctg cgg cga cac cac tca gat ctc tac tcg cac tac tac ttt ggg Leu Pro Leu Arg Arg His His Ser Asp Leu Tyr Ser His Tyr Phe Gly 440 445 450	1519
ggc ctt gcg gaa acg gtg ctg gtc aga tct atg tcc acc ttg ctc Gly Leu Ala Glu Thr Val Leu Val Val Arg Ser Met Ser Thr Leu Leu 455 460 465	1567
aac tat gac tat gtg tgg gat acg gtc ttc cac ccc agt ggg gcc ata Asn Tyr Asp Tyr Val Trp Asp Thr Val Phe His Pro Ser Gly Ala Ile 470 475 480 485	1615
gaa ata cga ttc tat gcc acg ggc tac atc agc tcg gca ttc ctc ttt Glu Ile Arg Phe Tyr Ala Thr Gly Tyr Ile Ser Ser Ala Phe Leu Phe 490 495 500	1663
ggc gct act ggg aag tac ggg aac caa gtg tca gag cac acc ctg ggc Gly Ala Thr Gly Lys Tyr Gly Asn Gln Val Ser Glu His Thr Leu Gly 505 510 515	1711

- 4 -

acg gtc cac acc cac agc gcc cac ttc aag gtg gat ctg gat gta gca	520	525	530	1759
Thr Val His Thr His Ser Ala His Phe Lys Val Asp Leu Asp Val Ala				
gga ctg gag aac tgg gtc tgg gcc gag gat atg gtc ttt gtc ccc atg	535	540	545	1807
Gly Leu Glu Asn Trp Val Trp Ala Glu Asp Met Val Phe Val Pro Met				
gct gtg ccc tgg agc cct gag cac cag ctg cag agg ctg cag gtg acc	550	555	560	1855
Ala Val Pro Trp Ser Pro Glu His Gln Leu Gln Arg Leu Gln Val Thr				
cgx aag ctg ctg gag atg gag cag gcc ttc ctc gtg gga agc	570	575	580	1903
Arg Lys Leu Leu Glu Glu Gln Ala Ala Phe Leu Val Gly Ser				
gcc acc cct cgc tac ctg tac ctg gcc agc aac cac agc aac aag tgg	585	590	595	1951
Ala Thr Pro Arg Tyr Leu Tyr Leu Ala Ser Asn His Ser Asn Lys Trp				
ggx cac ccc cgg ggc tac cgc atc cag atg ctc agc ttt gct gga gag	600	605	610	1999
Gly His Pro Arg Gly Tyr Arg Ile Gln Met Leu Ser Phe Ala Gly Glu				
ccg ctg ccc caa aac agc tcc atg gcg aga ggc ttc agc tgg gag agg	615	620	625	2047
Pro Leu Pro Gln Asn Ser Ser Met Ala Arg Gly Phe Ser Trp Glu Arg				
tac cag ctg gct gtg acc cag cgg aag gag gag gag ccc agt agc agc	630	635	640	2095
Tyr Gln Leu Ala Val Thr Gln Arg Lys Glu Glu Pro Ser Ser Ser				
agc gtt ttc aat cag aat gac cct tgg gcc ccc act gtg gat ttc agt	650	655	660	2143
Ser Val Phe Asn Gln Asn Asp Pro Trp Ala Pro Thr Val Asp Phe Ser				
gac ttc atc aac aat gag acc att gct gga aag gat ttg gtg gcc tgg	665	670	675	2191
Asp Phe Ile Asn Asn Glu Thr Ile Ala Gly Lys Asp Leu Val Ala Trp				
gtg aca gct ggt ttt ctg cat atc cca cat gca gag gac att cct aac	680	685	690	2239
Val Thr Ala Gly Phe Leu His Ile Pro His Ala Glu Asp Ile Pro Asn				
aca gtg act gtg ggg aac ggc gtg ggc ttc ttc ctc cga ccc tat aac	695	700	705	2287
Thr Val Thr Val Gly Asn Gly Val Gly Phe Phe Leu Arg Pro Tyr Asn				
tcc ttt gac gaa gac ccc tcc ttc tac tct gcc gac tcc atc tac ttc	710	715	720	2335
Phe Phe Asp Glu Asp Pro Ser Phe Tyr Ser Ala Asp Ser Ile Tyr Phe				
cga ggg gac cag gat gct ggg gcc tgc gag gtc aac ccc cta gct tgc	730	735	740	2383
Arg Gly Asp Gln Asp Ala Gly Ala Cys Glu Val Asn Pro Leu Ala Cys				

- 5 -

ctg ccc cag gct gcc tgt gcc ccc gac ctc cct gcc ttc tcc cac	2431
Leu Pro Gln Ala Ala Ala Cys Ala Pro Asp Leu Pro Ala Phe Ser His	
745 750 755	
ggg ggc ttc tct cac aac tag gcggtcctgg gatggggcat gtggccaagg	2482
Gly Gly Phe Ser His Asn	
760	
gctccagggc cagggtgtga gggatggga gcagctggc actgggccgg cagcctggtt	2542
ccctcttcc tggccagga ctctcttct tccactaccc tccctcgcat ccgcctctga	2602
gccaggagcc tcctgaccct gtgatgcctg acacagggga cactgaacct tggatgcc	2662
agctgtactg agttctatc cacagaggcc aggcattggcc cagcctggag ccgtggccga	2722
gggctccct agatggttcc ctttggctt gtctggctt cccgaatctt tttaggccac	2782
ctccaaggac tctaaaaggg ggctattccc tggagacccc agagtagggt tgccagtcct	2842
gcaagtccat agctgagctg gaaaggatgc ttctgctcac attccctctc atccagggtcc	2902
tttccttctc gtcttcctct ctctcaccta cttcctcctc ctcttcctgt ctctgccttc	2962
tcttcatacc tgcaatttct cccgaatcct gagggatata ccctatgtcc cagccccctgg	3022
tactccccca gcctcagtt ttcagtcaag ttccgtctcc tctccagccc tatggaagtc	3082
tcaaggtcac gggaccccta atcagagtgg ccaatccctg tggatgcctt ctttggctct	3142
gttgcattt gggagtagga gttgctccta cccctgtctt gggctgggt gtgtttcagg	3202
acagctgctt ctgtgcattt gtgtctgcct gcctcatgt ctctatacgt gaggatggtc	3262
atcgtgacag cagcagctca agtttagcatt tcaagtgtt tgggggtgca atgataatga	3322
agaatggcca ttttgcacca gggctctgta ttctgcaaca gcctgtttgg gaggctggag	3382
tggaaacaaa ggggtggcat caaagatgag aagccaaagc ccctacaact ccagccaccc	3442
agccaggagg ggctgtccaa tcacattcag gcatgcaat gagctgggcc ctgggtgagg	3502
tgggggtctg gccttagtggg gaggggcctg gcctgggtgg ggcaggccct gcctgggtcc	3562
aggcttgggc tccattccca tcactgtgt ccctcctgag gtctggattt gggatgggaa	3622
caaagaaata gcaagagatg agaaacaaca gaaactttt tctctaaagg actggtaaaa	3682
tcaattctga tacagcctta caatacataa gtatgcagct aaaaataat tgtatgttt	3742
tatataactaa tatgtataaa tcttcaggtg aaaaaggcaa gccacagaaa tgtgtatagc	3802
gcacttccca tttgtgttcc agaaaggagt agaatataaa cacataattt cttatgtatg	3862
cctattcaga ataaatgggt aacactgatt actttggga gggaaaccag taggttgagg	3922
acaggagagg gaagggtctt aacacttaca ccctttgtta cattttgaat tttgaaccat	3982

- 6 -

gtgactgtat tacctattca aaataaacaa taaatggcc caaaaaaaaaaaaaaaa aaaaaaaaaa 4040

<210> 2
<211> 763
<212> PRT
<213> human

<400> 2

Met Asn Gln Lys Thr Ile Leu Val Leu Leu Ile Leu Ala Val Ile Thr
1 5 10 15

Ile Phe Ala Leu Val Cys Val Leu Leu Val Gly Arg Gly Gly Asp Gly
20 25 30

Gly Glu Pro Ser Gln Leu Pro His Cys Pro Ser Val Ser Pro Ser Ala
35 40 45

Gln Pro Trp Thr His Pro Gly Gln Ser Gln Leu Phe Ala Asp Leu Ser
50 55 60

Arg Glu Glu Leu Thr Ala Val Met Arg Phe Leu Thr Gln Arg Leu Gly
65 70 75 80

Pro Gly Leu Val Asp Ala Ala Gln Ala Arg Pro Ser Asp Asn Cys Val
85 90 95

Phe Ser Val Glu Leu Gln Leu Pro Pro Lys Ala Ala Ala Leu Ala His
100 105 110

Leu Asp Arg Gly Ser Pro Pro Pro Ala Arg Glu Ala Leu Ala Ile Val
115 120 125

Phe Phe Gly Arg Gln Pro Gln Pro Asn Val Ser Glu Leu Val Val Gly
130 135 140

Pro Leu Pro His Pro Ser Tyr Met Arg Asp Val Thr Val Glu Arg His
145 150 155 160

Gly Gly Pro Leu Pro Tyr His Arg Arg Pro Val Leu Phe Gln Glu Tyr
165 170 175

Leu Asp Ile Asp Gln Met Ile Phe Asn Arg Glu Leu Pro Gln Ala Ser
180 185 190

Gly Leu Leu His His Cys Cys Phe Tyr Lys His Arg Gly Arg Asn Leu
195 200 205

Val Thr Met Thr Thr Ala Pro Arg Gly Leu Gln Ser Gly Asp Arg Ala
210 215 220

Thr Trp Phe Gly Leu Tyr Tyr Asn Ile Ser Gly Ala Gly Phe Phe Leu
225 230 235 240

His His Val Gly Leu Glu Leu Leu Val Asn His Lys Ala Leu Asp Pro
245 250 255

- 7 -

Ala Arg Trp Thr Ile Gln Lys Val Phe Tyr Gln Gly Arg Tyr Tyr Asp
260 265 270

Ser Leu Ala Gln Leu Glu Ala Gln Phe Glu Ala Gly Leu Val Asn Val
275 280 285

Val Leu Ile Pro Asp Asn Gly Thr Gly Ser Trp Ser Leu Lys Ser
290 295 300

Pro Val Pro Pro Gly Pro Ala Pro Pro Leu Gln Phe Tyr Pro Gln Gly
305 310 315 320

Pro Arg Phe Ser Val Gln Gly Ser Arg Val Ala Ser Ser Leu Trp Thr
325 330 335

Phe Ser Phe Gly Leu Gly Ala Phe Ser Gly Pro Arg Ile Phe Asp Val
340 345 350

Arg Phe Gln Gly Glu Arg Leu Val Tyr Glu Ile Ser Leu Gln Glu Ala
355 360 365

Leu Ala Ile Tyr Gly Gly Asn Ser Pro Ala Ala Met Thr Thr Arg Tyr
370 375 380

Val Asp Gly Gly Phe Gly Met Gly Lys Tyr Thr Thr Pro Leu Thr Arg
385 390 395 400

Gly Val Asp Cys Pro Tyr Leu Ala Thr Tyr Val Asp Trp His Phe Leu
405 410 415

Leu Glu Ser Gln Ala Pro Lys Thr Ile Arg Asp Ala Phe Cys Val Phe
420 425 430

Glu Gln Asn Gln Gly Leu Pro Leu Arg Arg His His Ser Asp Leu Tyr
435 440 445

Ser His Tyr Phe Gly Gly Leu Ala Glu Thr Val Leu Val Val Arg Ser
450 455 460

Met Ser Thr Leu Leu Asn Tyr Asp Tyr Val Trp Asp Thr Val Phe His
465 470 475 480

Pro Ser Gly Ala Ile Glu Ile Arg Phe Tyr Ala Thr Gly Tyr Ile Ser
485 490 495

Ser Ala Phe Leu Phe Gly Ala Thr Gly Lys Tyr Gly Asn Gln Val Ser
500 505 510

Glu His Thr Leu Gly Thr Val His Thr His Ser Ala His Phe Lys Val
515 520 525

Asp Leu Asp Val Ala Gly Leu Glu Asn Trp Val Trp Ala Glu Asp Met
530 535 540

- 8 -

Val Phe Val Pro Met Ala Val Pro Trp Ser Pro Glu His Gln Leu Gln
545 550 555 560

Arg Leu Gln Val Val Thr Arg Lys Leu Leu Glu Met Glu Glu Gln Ala Ala
565 570 575

Phe Leu Val Gly Ser Ala Thr Pro Arg Tyr Leu Tyr Leu Ala Ser Asn
580 585 590

His Ser Asn Lys Trp Gly His Pro Arg Gly Tyr Arg Ile Gln Met Leu
595 600 605

Ser Phe Ala Gly Glu Pro Leu Pro Gln Asn Ser Ser Met Ala Arg Gly
610 615 620

Phe Ser Trp Glu Arg Tyr Gln Leu Ala Val Thr Gln Arg Lys Glu Glu
625 630 635 640

Glu Pro Ser Ser Ser Val Phe Asn Gln Asn Asp Pro Trp Ala Pro
645 650 655

Thr Val Asp Phe Ser Asp Phe Ile Asn Asn Glu Thr Ile Ala Gly Lys
660 665 670

Asp Leu Val Ala Trp Val Thr Ala Gly Phe Leu His Ile Pro His Ala
675 680 685

Glu Asp Ile Pro Asn Thr Val Thr Val Gly Asn Gly Val Gly Phe Phe
690 695 700

Leu Arg Pro Tyr Asn Phe Phe Asp Glu Asp Pro Ser Phe Tyr Ser Ala
705 710 715 720

Asp Ser Ile Tyr Phe Arg Gly Asp Gln Asp Ala Gly Ala Cys Glu Val
725 730 735

Asn Pro Leu Ala Cys Leu Pro Gln Ala Ala Ala Cys Ala Pro Asp Leu
740 745 750

Pro Ala Phe Ser His Gly Gly Phe Ser His Asn
755 760

<210> 3
<211> 739
<212> DNA
<213> S.japonicum

<220>
<221> CDS
<222> (17)..(673)

<300>
<308> GenBank/M14654
<309> 1994-03-14

-9-

<400> 3
 ttttaggttaac ttggtc atg tcc cct ata cta ggt tat tgg aaa att aag ggc
 Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly
 1 5 10
 ctt gtg caa ccc act cga ctt ctt ttg gaa tat ctt gaa gaa aaa tat
 Leu Val Gln Pro Thr Arg Leu Leu Glu Tyr Leu Glu Glu Lys Tyr
 15 20 25
 100
 gaa gag cat ttg tat gag cgc gat gaa ggt gat aaa tgg cga aac aaa
 Glu Glu His Leu Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys
 30 35 40
 148
 aag ttt gaa ttg ggt ttg gag ttt ccc aat ctt cct tat tat att gat
 Lys Phe Glu Leu Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp
 45 50 55 60
 196
 ggt gat gtt aaa tta aca cag tct atg gcc atc ata cgt tat ata gct
 Gly Asp Val Lys Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala
 65 70 75
 244
 gac aag cac aac atg ttg ggt ggt tgg cca aaa gag cgt gca gag att
 Asp Lys His Asn Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile
 80 85 90
 292
 tca atg ctt gaa gga gcg gtt ttg gat att aga tac ggt gtt tcg aga
 Ser Met Leu Glu Gly Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg
 95 100 105
 340
 att gca tat agt aaa gac ttt gaa act ctc aaa gtt gat ttt ctt agc
 Ile Ala Tyr Ser Lys Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser
 110 115 120
 388
 aag cta cct gaa atg ctg aaa atg ttc gaa gat cgt tta tgt cat aaa
 Lys Leu Pro Glu Met Leu Lys Met Phe Glu Asp Arg Leu Cys His Lys
 125 130 135 140
 436
 aca tat tta aat ggt gat cat gta acc cat cct gac ttc atg ttg tat
 Thr Tyr Leu Asn Gly Asp His Val Thr His Pro Asp Phe Met Leu Tyr
 145 150 155
 484
 gac gct ctt gat gtt tta tac atg gac cca atg tgc ctg gat gcg
 Asp Ala Leu Asp Val Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala
 160 165 170
 532
 ttc cca aaa tta gtt tgt ttt aaa aaa cgt att gaa gct atc cca caa
 Phe Pro Lys Leu Val Cys Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln
 175 180 185
 580
 att gat aag tac ttg aaa tcc agc aag tat ata gca tgg cct ttg cag
 Ile Asp Lys Tyr Leu Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln
 190 195 200
 628
 ggc tgg caa gcc acg ttt ggt ggt ggc gac cat cct cca aaa taa
 Gly Trp Gln Ala Thr Phe Gly Gly Asp His Pro Pro Lys
 205 210 215
 673

- 10 -

attaaagaatg attgttttag taaacattat ttatcactta caattaaact aaatataaat 733
gtcgac 739

<210> 4
<211> 218
<212> PRT
<213> *S. japonicum*

<400> 4
Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val Gln Pro
1 5 10 15

Thr Arg Leu Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu His Leu
20 25 30

Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe Glu Leu
 35 40 45

Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp Val Lys
50 55 60

Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp Lys His Asn
65 70 75 80

Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile Ser Met Leu Glu
85 90 95

Gly Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg Ile Ala Tyr Ser
100 105 110

Lys Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser Lys Leu Pro Glu
 115 120 125

Met Leu Lys Met Phe Glu Asp Arg Leu Cys His Lys Thr Tyr Leu Asn
130 135 140

Gly Asp His Val Thr His Pro Asp Phe Met Leu Tyr Asp Ala Leu Asp
145 150 155 160

Val Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala Phe Pro Lys Leu
165 170 175

Val Cys Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp Lys Tyr
180 185 190

Leu Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly Trp Gln Ala
195 200 205

Thr Phe Gly Gly Gly Asp His Pro Pro Lys
210 215

- 11 -

<210> 5
<211> 217
<212> PRT
<213> S.japonicum

<400> 5
Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val Gln Pro Thr
1 5 10 15
Arg Leu Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu His Leu Tyr
20 25 30
Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe Glu Leu Gly
35 40 45
Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp Val Lys Leu
50 55 60
Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp Lys His Asn Met
65 70 75 80
Leu Gly Gly Ser Pro Lys Glu Arg Ala Glu Ile Ser Met Leu Glu Gly
85 90 95
Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg Ile Ala Tyr Ser Lys
100 105 110
Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser Lys Leu Pro Glu Met
115 120 125
Leu Lys Met Phe Glu Asp Arg Leu Ser His Lys Thr Tyr Leu Asn Gly
130 135 140
Asp His Val Thr His Pro Asp Phe Met Leu Tyr Asp Ala Leu Asp Val
145 150 155 160
Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala Phe Pro Lys Leu Val
165 170 175
Ser Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp Lys Tyr Leu
180 185 190
Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly Trp Gln Ala Thr
195 200 205
Phe Gly Gly Asp His Pro Pro Lys
210 215

Fig. 1




Fig. 2




Fig. 3

